WATSON LABS INC Company Profile
✉ Email this page to a colleague
What is the competitive landscape for WATSON LABS INC, and what generic and branded alternatives to WATSON LABS INC drugs are available?
WATSON LABS INC has seventy-five approved drugs.
There are eleven tentative approvals on WATSON LABS INC drugs.
Summary for WATSON LABS INC
| US Patents: | 0 |
| Tradenames: | 60 |
| Ingredients: | 60 |
| NDAs: | 75 |
Drugs and US Patents for WATSON LABS INC
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs Inc | PERPHENAZINE | perphenazine | TABLET;ORAL | 207582-001 | Oct 17, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs Inc | LEVETIRACETAM | levetiracetam | TABLET;ORAL | 078797-004 | Jan 15, 2009 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Watson Labs Inc | TADALAFIL | tadalafil | TABLET;ORAL | 205885-004 | Mar 29, 2019 | AB1 | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Watson Labs Inc | IRBESARTAN AND HYDROCHLOROTHIAZIDE | hydrochlorothiazide; irbesartan | TABLET;ORAL | 091539-002 | Oct 22, 2012 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Watson Labs Inc | EZETIMIBE AND SIMVASTATIN | ezetimibe; simvastatin | TABLET;ORAL | 202968-001 | Apr 26, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
